• Senesco Technologies Inc., of Bridgewater, N.J., said it completed the first cohort of patients in its Phase Ib/IIa trial in multiple myeloma, showing that SNS01-T was safe and well tolerated and met the criteria for stable disease in two of the three evaluable patients.